Answers are grounded in this paper and cite their sources.
Cohort study demonstrates accurate 10-year progression and mortality predictions in prostate cancer, highlighting the value of dynamic Markov models for long-term risk assessment.
Prostate cancer progression varies across patients. Understanding disease trajectories and mortality risk is important for improved healthcare. This study developed a time-inhomogeneous Markov model using territory-wide electronic medical records from Hong Kong to estimate 10-year disease progression. The model was constructed using data from 3,274 patients newly diagnosed in 2010–2012. Their electronic medical records defined baseline covariates (age, Charlson Comorbidity Index [CCI], and prostate-specific antigen [PSA] level) and time-varying health states. Mild cases (age≤65, CCI=0, PSA≤4 ng/mL) were predicted to have 16.9% and 28.0% mortality at five and ten years. Evaluated on an independent 2013 cohort, our model showed strong prediction performance for metastasis-free survival (concordance index [C-index]: 0.780; 95% confidence interval [CI]: 0.723–0.837) and overall survival (C-index: 0.787; 95% CI: 0.731–0.843), exceeding Cox proportional hazards and random survival forest models. This study provides a pragmatic tool for long-term progression risk prediction and health economic evaluation.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: